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Abstract
Background: Cytomegalovirus (CMV) is responsible for a wide range of diseases in neonates, and
has been recognized as a major cause of congenital defects in developed countries for many years.
More children suffer serious disabilities caused by congenital CMV than by several better-known
childhood maladies. Insight into the epidemiology of congenital CMV disease is needed for the
assessment of preventive strategies.
Methods: Using data from the National Hospital Morbidity Database (NHMD) complied by the
Australian Institute of Health and Welfare (AIHW), we examined the rates of hospital admissions
for children diagnosed with congenital cytomegalovirus (CMV) by year, sex, age group and length
of stay.
Results: Over an 8-year period (1993–2001), there were 1314 admissions for the congenital form
of CMV disease. Of these admissions, 25% were principally hospitalized because of congenital CMV.
The average annual rate of admissions in children aged 0–4, 5–9 and 10–14 years was 9.40, 2.40
and 0.85 per 100,000 Australian population respectively.
Conclusion: Compared with many other congenital illnesses, which are now vaccine preventable,
the burden of congenital CMV is comparatively high. A vaccination program would be justifiable
should a vaccine become available.
Background
An estimated 20 000 – 40 000 infants are born each year
with congenital cytomegalovirus (CMV) infection in the
United States alone. About 100–200 of these infants will
die as a consequence of symptomatic infection and a fur-
ther 4000–8000 will develop permanent neurological
complications that often lead to permanent disabilities
[1]. Higher estimates of the burden of congenital CMV in
terms of death and disability have also been published
[2,3].
The number of US infants experiencing symptoms from
congenital CMV infections exceeds the number of new-
borns affected by other, better-known childhood diseases
and syndromes, such as congenital rubella, fetal alcohol
syndrome, down's syndrome and neural tube defect [4,5].
While this large difference in occurrence is partly due to
improvements in the screening and prevention of these
other conditions, congenital CMV infections have
occurred at these high rates for decades. Before the devel-
opment and availability of the rubella vaccine, it was
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noted that the year-in and year-out toll of CMV infection
exceeded that of rubella, but the impact of rubella was
more dramatic because it was epidemic in nature [6].
Most children with asymptomatic congenital CMV infec-
tion develop normally without any permanent cognitive,
perceptual or motor deficits [4,6]. However, for some chil-
dren who are asymptomatic at birth there is the risk that
they may develop CMV-related symptoms, such as visual
impairment [5,7-11]. Some researchers have suggested
that asymptomatic congenital CMV infection can impair
intellectual development and neurophysiologic perform-
ance [12-15]. Although visual impairment is less common
in asymptomatic infants compared to those who are
symptomatic at birth; chorioretinitis, optic atrophy, stra-
bismus and pigmentary retinopathy do occur in 1.2%–
3.9% of cases [11,16,17]. Each year, an estimated 2,600
children develop chorioretinitis or optic atrophy in the
United States from asymptomatic congenital CMV infec-
tions, with approximately 15% having a visual acuity of
worse than 20/50 in one eye [11].
For infants with symptomatic congenital CMV infection
the outcome is poor [18]. Around 10%–15% will experi-
ence symptoms at birth [7]. Jaundice, hepatosplenomeg-
aly and petechiae are the most frequently reported signs of
congenital CMV infection in the neonate, being present in
up to two thirds of overtly infected infants [5,19,20]. Neu-
rological signs of congenital CMV infection include
microcephaly, mental retardation (IQ<70), motor abnor-
malities, sensorineural hearing loss (bilateral and unilat-
eral), chorioretinitis and other visual defects and seizures
[17,21-24]. Sensorineural hearing loss (SNHL) is the most
common symptom of CMV infection among the 10–15%
of children with symptoms of infections at birth [25,26].
These cases account for at least one-third of all SNHL in
children [27]. While there are multiple causes of hearing
loss, CMV is the only significant viral cause of hearing
loss, since the introduction of vaccination for measles,
mumps and rubella, has made hearing loss from those
causes extremely rare [28].
Children with congenital CMV-induced sequelae have a
wide range of special needs, and they often require exten-
sive interventions from health care providers, such as
cochlear implantation, speech therapy, neurodevelop-
mental assessments, and, in severe cases, lifelong custo-
dial care.
As a vaccine for CMV may one day be available, under-
standing the pre-vaccination burden of CMV disease is
useful for planning future prevention programs. To exam-
ine the epidemiology of congenital CMV in Australia, a
retrospective review of hospital admissions was under-
taken. The objectives were to analyze the rate, temporal
trends and patient mortality associated with these hospi-
tal admissions.
Methods
A retrospective analysis of hospital discharge records from
1993 to 2001 was conducted. The data were drawn from
the National Hospital Morbidity Database (NHMD) com-
plied by the Australian Institute of Health and Welfare
(AIHW) from data supplied by the State and Territory
health authorities [29]. The NHMD is a collection of elec-
tronic confidentialised summary records for admitted
patients dying/discharged from public and private acute
and psychiatric hospitals as well as private free-standing
hospital facilities in Australia. The National Health Data
Dictionary definitions form the bases of the databases,
ensuring a high standard of data comparability. Hospital-
izations were chosen because they were more accessible in
the database and less subject to interpretation than outpa-
tient cases of CMV disease. Ethical clearance for the over-
all study was sought and obtained from the Western
Sydney Area Health Service.
Data was extracted on patients admitted into hospital
with either a principal or non-principal diagnosis of con-
genital CMV. Patients with a non-principal diagnosis were
also included to get a more complete picture of the bur-
den of disease attributable to CMV. All data used had been
previously de-identified by the AIHW. The data were ana-
lyzed by financial year based on the date of hospital dis-
charge. All patients discharged between July 1, 1993 and
June 30, 2001 was included. Hospital discharge diagnoses
and procedures were coded in accordance with the Inter-
national Classification of Diseases, 9th and 10th Revision
(ICD9 and ICD10) Australian Modification. Any admis-
sion with a specific congenital CMV ICD 9 code: 777.1 for
the period 1993–1998, or ICD-10: P35.1 for the period
1999–2001, was included.
The age groups were 0–4, 5–9 and 10–14 years. A record
is included for each separation, not for each patient, so
patients who separated more than once in the year have
more than one record in the database. The variables that
were extracted for analysis included: sex, age, length of
stay, separation mode (which includes death as an out-
come of hospitalization) and diagnosis. Data from all
States and Territories were available for analysis.
In addition to examining the geographic location of the
admission, the Rural, Remote and Metropolitan Areas
(RRMA) classification was also examined. This classifica-
tion was developed in 1995 to differentiate between
regions. The RRMA has seven categories, which collapse
into three zones. The metropolitan zone includes the cat-
egories capital cities and other metropolitan centers; the
rural zone includes large rural centers, small rural centersBMC Pediatrics 2009, 9:7 http://www.biomedcentral.com/1471-2431/9/7
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and other rural areas, while the remote zone includes
remote centers and other remote areas. RRMA values are
based on the population density of the Statistical Local
Area (SLA).
Rates were calculated using Australian Bureau of Statistics
(ABS) mid-year estimated resident information for chil-
dren and adolescents aged 0–14 years [30]. Rates are pre-
sented as annual rates or average annual rates per 100 000
population (0–14 years) or population in age, sex as
appropriate. Average annual rates were calculated by
dividing the total number of cases for the period of inves-
tigation by the sum of each year's population for the same
period. For hospitalization data, the midyear population
estimate for the first half of the financial year was used as
the denominator.
Results
From July 1993 to June 2001, there were 1314 admissions
for children (aged ≤ 14 years) diagnosed with congenital
CMV disease, giving an average annual rate of 4.2 cases
per 100,000 children ≤ 14 years. The rate peaked in 1996–
1997 at 5.7 cases per 100,000 and then declined to 2.6
cases per 100,000 in 2000–2001 (Figure 1).
The average age specific annual rate of admission for chil-
dren aged 0–4, 5–9 and 10–14 years was 9.40, 2.40 and
0.85 per 100,000 respectively between 1993 and 2001
(Table 1). The overall male to female ratio was 1.3:1
admissions. The average annual rate of male admissions
for the eight years (4.0 cases per 100,000 male population
aged ≤ 14 years) exceeded the female rate (3.1 cases per
100,000 female population aged ≤ 14 years). Over the
eight year period, 39,818 bed days (average 4977 days per
year) were recorded. The mean length of stay was 30 days,
whilst the median length of stay was 7 days (range: 1 to 86
days), and 34% of hospitalizations were for 48 hours or
less.
Out of the 1314 hospital admissions, 57.9% were
recorded for a patient aged ≤ 23 months. The average
annual admission rate for infants aged ≤ 23 was 62.3 per
100,000 Table 2). Over the eight year period, admissions
peaked for children aged <1 month in 1996–1997, after
which time admissions declined again. For the other age
groups, there were minor peaks registered for each group,
but they were not as dramatic as they were for the young-
est age category (Figure 2). In patients aged less than one
month, the average annual admission rate was 443 per
100,000 compared to only 9.3 per 100,000 for children
aged between 10 and 23 months. Females accounted for
50% of all admissions for this age bracket. Children aged
four months and over had a significantly lower risk of
being hospitalized with CMV compared with children
aged less than one month, and this risk decreased with
increasing age. All fatal cases of CMV were in children
aged less than 12 months (23 cases over 8 years).
The highest average annual rate of admissions was
recorded for the Northern Territory (5.68 per 100,000 NT
population), followed by New South Wales (4.40 per
100,000 NSW population) and the South Australia (3.49
per 100,000 SA population). The highest annual rate of
admission was 20.6 per 100,000, recorded in the North-
ern Territory in 1996–1997. This was followed by 10.9 per
100,000 in the Australian Capital Territory in 1997–1998
and 8.33 per 100,000 in South Australia in 1996–1997.
Information on the RRMA was available from 1995
onwards for the admissions with congenital CMV. From
the database, we found that 71.7% (741/1033) of admis-
sions were classified as being in a metropolitan area,
18.2% (188/1033) were in rural areas, 4.6% (48/1033)
were in remote areas and 5% (56/1033) were not coded.
Of the remote hospitalizations, 54% (26/48) were from
the Northern Territory, 21% (10/48) were from South
Australia and 12.5% (6/48) from both Queensland and
Western Australia.
Discussion
The rate of admissions for congenital CMV was found to
be highest in infants aged less than five years, amongst
whom the average annual hospitalization rate was 9.40
cases per 100,000 population. This group accounted for
the highest percentage of hospitalizations (74%) and all
deaths. This probably reflects the fact that the likelihood
of diagnosis is highest in this age group.
One of the aims of this paper was to assess the burden that
congenital CMV has on the health system. From the
NHMD, it was established that over the eight years, con-
Congenital CMV age-specific hospital rates by age group  (aged ≤ 14 years) and year of diagnosis, Australia, July 1993  to June 2001 Figure 1
Congenital CMV age-specific hospital rates by age 
group (aged ≤ 14 years) and year of diagnosis, Aus-
tralia, July 1993 to June 2001.BMC Pediatrics 2009, 9:7 http://www.biomedcentral.com/1471-2431/9/7
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genital CMV was the principal cause of admission in 329
cases, and was diagnosed in a further 985 admissions. It is
well recognized that children with symptomatic congeni-
tal CMV require complex medical and surgical care as a
result of the consequences of this infection. Previous stud-
ies have estimated that the disease burden associated with
congenital CMV disease in the early 1990's, cost the US
healthcare system approximately $US1.9 billion annu-
ally, and a cost per affected child of over $US300, 0000
[31]. These costs reflect the lifelong disability associated
with symptomatic infection, since patients often require
long-term residential care and extensive medical interven-
tion [32]. To the best of our knowledge, the costs associ-
ated with congenital CMV disease have not been
calculated in Australia. From the information obtained
from the NHMD, it is possible to calculate the cost per
case associated with a hospital visit. This performance
indicator is a measure of the average cost of providing care
for an admitted patient, adjusted for the relative complex-
ity of the patient's condition and hospital services pro-
vided. Although this calculation is not specific to patients
with CMV disease, it does provide a rough estimate of the
costs attributable to the disease. For example, in 2000–
2001, the cost per case mix-adjusted separation was
$2,834. As there were 104 admissions, the estimated cost
attributable to congenital CMV for that year would be
$294 736. Further studies would need to be conducted to
ascertain financial costs associated with this disease.
The second aim was to establish up-to-date estimates of
the burden of congenital CMV in Australia. Due to the
nature of the hospital database used in this study, it was
impossible to ascertain a true estimate of the burden, as
we could not separate children who had recurrent admis-
sions. There are however, a number of previous studies
which have tried to document the rate of congenital CMV
in Australia. One of the first studies [33] examined 47,320
consecutive live births at an obstetric hospital, and found
that one in every 4000 child born had evidence of neona-
tal cytomegalic inclusion disease (CID). From these
results, the authors suggested that a very low rate of dis-
ease existed in Australia for congenital CMV. However,
this study was limited to only including children who
were symptomatic at birth and excluded any asympto-
matic children, therefore underestimating the burden of
the disease. Given that 80–90% of infected children are
asymptomatic at birth, extrapolation of the reported inci-
dence from the study provided an estimate of total inci-
dence closer to 0.2–0.3% [34]. In a later study, Sfameni et
al., found that firstly 71% of the pregnant women
screened in the study had antibodies to CMV at their first
antenatal visit and secondly that primary CMV infection
occurred in five of 338 (1.5%) initially seronegative
women whose sera were retested at the end of their preg-
nancies. On the basis of these observations the authors
estimated that congenital CMV infection due to primary
maternal infection occurred in up to 2 in 1,000 infants in
the community [35]. However, this calculation also does
not account for all illness associated with CMV. In 2005,
Table 1: CMV hospitalisations by age group (0–14 years), Australia, July 1993–June 2001
Age group (years) Hospitalisations July 1993–June 2001 LOS* per admission (days) Deaths (number)
No. (PD †) Rate‡ Median No. (PD †)
0–4 971 (150) 9.40 15 23 (8)
5–9 253 (137) 2.40 2 0
10–14 90 (42) 0.85 5 0
Total 1314 (329) 3.2 7 23
†PD = principal diagnosis
*LOS = length of stay in hospital
‡ Average annual age-specific rate per 100,000 population
Table 2: CMV hospitalisations by age group (<1–23 months), Australia, July 1993 – June 2001
Age Group (months) Hospitalisations July 1993–June 2001 Average annual rate per 100,000
No. %
<1 452 59.4 443.7
1–4 165 21.7 162.0
5–9 59 7.8 57.9
10–23 85 11.2 9.3
TOTAL 761 100 62.3BMC Pediatrics 2009, 9:7 http://www.biomedcentral.com/1471-2431/9/7
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Munro et al. used the primary infection rate described by
Sfameni in 1986 (1.5%) and the number of births in Aus-
tralian and estimated that approximately 1476 babies are
born with congenital CMV in Australia and that 15%
show symptoms at birth [36]. However, this is again still
not a true reflection of the burden of CMV in Australia, as
it only reflects only symptomatic cases at birth.
Worldwide, there are 15 surveillance units, which make
up the International Network of Pediatric Surveillance
Units (INoPSU) [37]. The network was established in
1998 to collectively conduct surveillance of uncommon
conditions of childhood. Australia, Britain and Canada
are the only countries which have undertaken active sur-
veillance for congenital CMV. In Britain, during the 25
months of surveillance, 288 reports were received, of
which 93 were confirmed cases, 69 suspected cases and 93
duplicate or error reports [38]. In Canada, surveillance,
commenced in March 2005 and by December 31, 2007,
there were 46 confirmed cases [39].
Although the surveillance systems used by the Network of
Pediatric Surveillance Units have a definite advantage over
more traditional passive reporting systems, complete case
ascertainment is unlikely, especially amongst rural and
Indigenous communities which are poorly served by pedi-
atricians. For example, in Canada, the rate of infection is
estimated to be around 1%, which would equate to
approximately 300 cases per year from the Canadian birth
cohort (assuming 10% of infants are symptomatic). This
means approximately only 7% of cases are being reported
the Canadian surveillance unit. The investigators suggest
that this may be due to a number of factors including: that
the neonatal symptoms may be subtle and not recognized
as congenital CMV early enough in the neonatal period, or
that the surveillance unit is only capturing a proportion of
the diagnosed cases in the country [39]. The most accurate
measurements of the infection rate will likely have to
await a population-based surveillance to capture the full
spectrum of congenital CMV in these countries. This has
been successfully implemented for other congenital dis-
ease such as rubella.
Previous studies assessing the cost benefits of routine
immunization for CMV, found that vaccination of healthy
women aged 15–25 years is cost beneficial even in popu-
lations where CMV seroprevalence is high. In popula-
tions, such as Australia, where there is lower
seroprevalence (57%), for every 100,000 women immu-
nized, more than 24 cases of symptomatic congenital
CMV infection at birth and a similar number of cases with
late sequelae (mainly deafness) would be prevented
yearly [31]. The Advisory Committee on Immunization
Practices also suggested that if a vaccine program were
implemented today, then the annualized present value of
the Quality Adjusted Life Year (QALY) gained would be
70,000, with a US$4 billion dollar saving in health care
costs [2]. These calculations were based on the assump-
tion that the vaccine would be 100% efficacious and uti-
lized by 100% of the target population (12-year-old boys
and girls).
In contrast with the required vaccination rates needed for
the elimination of measles (93%), mumps (93%) and
rubella (92%), studies have shown that CMV requires a
much lower rate of vaccination (60%). This is related to
the fact that CMV has a low force of infection and a rela-
tively low basic reproductive number (R0) of 2.5 [40]. R0
refers to the number of secondary infections caused by the
introduction of a single infectious case into a completely
susceptible population. The R0 for CMV is very similar to
that of smallpox (Ro: 2.3–3.4) which required a critical
vaccination proportion of 57% to 70% for eradication.
Therefore, even if the efficacy of a candidate CMV vaccine
was only 80–90% in preventing principal infection, the
disease could be eradicated by immunizing 66–75% of
the population [41]. However, just preventing principal
infections may not be adequate enough. In highly
immune populations secondary maternal infections,
rather than primary attacks, may be the leading cause of
intrauterine CMV infection [42]. Ahlfors et al. found that
in their long-term study of maternal and congenital CMV
infections that both primary and secondary infections
were equally responsible for congenital CMV infection
[6].
Our study has some limitations, mainly because of its reli-
ance on hospital discharge data for which accuracy
depends on the quality and consistency of coding by par-
ticipating hospitals. As there were no unique identifying
codes linking records for the same individual across data-
Number of hospital admissions for congenital CMV by age  group (aged ≤ 23 months) and year of diagnosis, Australia,  July 1993 to June 2001 Figure 2
Number of hospital admissions for congenital CMV 
by age group (aged ≤ 23 months) and year of diagno-
sis, Australia, July 1993 to June 2001.BMC Pediatrics 2009, 9:7 http://www.biomedcentral.com/1471-2431/9/7
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bases, it was not possible to extract recurrent hospital vis-
its for the same child. Therefore, data on some children
were represented more than once for any given year. For
hospitalizations where the CMV code was not the princi-
pal diagnosis, the CMV code will have been recorded as a
co-morbidity (additional or secondary diagnosis), the rel-
ative importance of which cannot be gauged.
Conclusion
These limitations notwithstanding, this nationwide look
at trends in hospital use for children diagnosed with con-
genital CMV in Australia provides data that can be used to
(1) justify the introduction of a vaccine when available,
(2) define future policies in an era of competing health
care priorities.
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